TALLC
  • Home
  • Our Company
    • About Us
    • Management Team
    • Scientific Advisors
    • Board of Directors
  • Our Science
    • Ocular Pain & Inflammation
    • SmartCelle TA-A001 for Eyes
    • SmartCelle Technology
  • Our Indications
    • Keratoconus Surgery PRK, LASIK and Cataracts Dry Eye and Glaucoma
    • Pipeline
  • Contact
    • Contact
    • News
Select Page

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

by taramac | Jul 7, 2020 | Uncategorized

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001 July 7, 2020 Montreal, Quebec Life Science Newswire – TALLC Corporation Inc. (TALLC) a pioneering pharmaceutical company using proprietary new molecular entities to...

Recent Posts

  • TALLC issues new Corporate Presentation
  • Dr. Damon Smith at Biotech Show Case
  • TALLC at the Ophthalmology Innovation Summit
  • TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001
  • Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC Inc.Follow

TALLC is an pioneering ophthalmology company focused on the unmet needs of patients with corneal and retinal conditions.

TALLC Inc.
4 Jan

TALLC and IACTA to present at the H.C. Wainwright Bioconnect Conference: January 10-13, 2022
https://lnkd.in/g5ZhR2Yn

TALLC will present details of the SmartCelle insoluble drug delivery platform for ocular, parenteral and oral delivery and an update on t…https://lnkd.in/gAwAqwnQ

Twitter 1478399366494777344
Load More...

Archives

  • January 2021
  • December 2020
  • November 2020
  • July 2020
  • May 2020

Categories

  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org